HemOnc Today New York
HemOnc Today New York
March 10, 2018
2 min watch
Save

VIDEO: CAR T-cell therapy has ‘incredible potency’ in chronic lymphocytic leukemia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — In this video commentary from HemOnc Today New York, co-program chair David L. Porter, MD, discussed the use of chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

CAR T cells have “incredibly potency” in CLL, said Porter, director of the cell therapy and transplant program at the University of Pennsylvania.

More than 50% of patients achieve a response, and 25% to 30% of patients achieve complete remission.

CAR T cells can persist for long periods of time in the blood, which may prevent relapse. Some data shows persistence for more than 5 years.

Toxicities, including cytokine release syndrome, appear to be manageable for the majority of patients.

“Overall, CAR T cells are going to be an important part of developing therapies for CLL and other B cell malignancies,” Porter said.

 

Disclosure: Porter reports intellectual property interests with Novartis.